Non-formulary methylphenidate ER (Ritalin LA®, and generics) will be covered on the prescription drug benefit when the following criteria are met:

- Patient is under 21 years of age -AND-
  Diagnosis of ADHD or ADD
  -OR-
- Patient is under Hospice care
  -OR-
- Diagnosis of ADHD or ADD -AND-

1) For patients NOT currently taking methylphenidate ER (Ritalin LA®, and generics):
   - Adequate trial** (7 days) of methylphenidate ER (Metadate CD), unless allergy to an inactive ingredient.

2) For patients currently taking methylphenidate ER (Ritalin LA®, and generics):
   - Adequate trial** (7 days) of methylphenidate ER (Metadate CD), unless allergy to an inactive ingredient.
   -OR-
   - Dose change only: patient meets current criteria and is already taking the drug

** Adequate trial of a short acting agent is further defined as wearing off that is not resolved by increasing the dose, AND adding a short-acting agent OR increasing frequency to twice daily OR clinically significant side effects related to the dosage form that cannot be resolved by adjusting the dose or timing.